皮肤鳞状细胞癌表观遗传学发病机制

doi:10.3760/cma.j.cn371439-20200123-00080

国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (9): 569-572.doi: 10.3760/cma.j.cn371439-20200123-00080

皮肤鳞状细胞癌表观遗传学发病机制

桑莹冰¹, 梁俊琴²()

¹新疆医科大学研究生学院,乌鲁木齐 830054
²新疆维吾尔自治区人民医院皮肤科,乌鲁木齐 830000

收稿日期:2020-01-23 修回日期:2020-05-13 出版日期:2020-09-08 发布日期:2020-10-27
通讯作者: 梁俊琴 E-mail:zyeemail@163.com
基金资助:
国家自然科学基金(81760494)

Epigenetic pathogenesis of cutaneous squamous cell carcinoma

Sang Yingbing¹, Liang Junqin²()

¹Department of Postgraduate, Xinjiang Medical University, Urumqi 830054, China
²Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China

Received:2020-01-23 Revised:2020-05-13 Online:2020-09-08 Published:2020-10-27
Contact: Liang Junqin E-mail:zyeemail@163.com
Supported by:
National Natural Science Foundation of China(81760494)

摘要/Abstract

摘要：

皮肤鳞状细胞癌(CSCC)是起源于表皮及其附属器角质形成细胞的一种恶性肿瘤,病因及发病机制复杂且尚不明确。CSCC的发病率在全球范围内总体上呈增长趋势,使得对其发病机制的研究日渐增多。表观遗传不改变基因组序列,通过DNA甲基化、组蛋白修饰、非编码RNA、染色质重塑等方式调控基因表达。其可逆、稳定的遗传特征将为CSCC发病机制研究提供新的思路。

关键词: 皮肤肿瘤, 肿瘤,鳞状细胞, DNA甲基化, 组蛋白密码, 非编码RNA

Abstract:

Cutaneous squamous cell carcinoma (CSCC) is a kind of malignant tumor originated from keratinocytes within the epidermis and its appendages. Its etiology and pathogenesis are complex and unclear. The incidence of CSCC is increasing in the whole world, which makes the research on its pathogenesis increasing day by day. Epigenetics does not change genome sequence, but regulates gene expression by DNA methylation, histone modification, noncoding RNA, chromatin remodeling and so on. Its reversible and stable genetic characteristics will provide a new idea for the study of pathogenesis of CSCC.

Key words: Skin neoplasms, Neoplasms, squamous cell, DNA methylation, Histone code, Non-coding RNA

桑莹冰, 梁俊琴. 皮肤鳞状细胞癌表观遗传学发病机制[J]. 国际肿瘤学杂志, 2020, 47(9): 569-572.

Sang Yingbing, Liang Junqin. Epigenetic pathogenesis of cutaneous squamous cell carcinoma[J]. Journal of International Oncology, 2020, 47(9): 569-572.

参考文献 22

[1]	Venables ZC, Nijsten T, Wong KF, et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K.2013-15: a cohort study[J]. Br J Dermatol, 2019,181(3):474-482. DOI: 10.1111/bjd.17873. doi: 10.1111/bjd.17873 pmid: 30864158
[2]	Stang A, Khil L, Kajüter H, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents[J]. J Eur Acad Dermatol Venereol, 2019,33 Suppl 8: 6-10. DOI: 10.1111/jdv.15967. doi: 10.1111/jdv.15318 pmid: 30811690
[3]	Umezono Y, Sato Y, Noto M, et al. Incidence rate of cutaneous squamous cell carcinoma is rapidly increasing in Akita Prefecture: urgent alert for super-aged society[J]. J Dermatol, 2019,46(3):259-262. DOI: 10.1111/1346-8138.14759. doi: 10.1111/1346-8138.14759 pmid: 30614560
[4]	Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns—results of a non-interventional study of the DeCOG[J]. Eur J Cancer, 2018,96:34-43. DOI: 10.1016/j.ejca.2018.01.075. doi: 10.1016/j.ejca.2018.01.075 pmid: 29665511
[5]	Ando M, Saito Y, Xu G, et al. Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers[J]. Nat Commun, 2019,10(1):2415. DOI: 10.1038/s41467-019-09937-w. doi: 10.1038/s41467-019-10557-7 pmid: 31142745
[6]	Li J, Hu WX, Luo SQ, et al. Promoter methylation induced epigene-tic silencing of DAZAP2, a downstream effector of p38/MAPK pathway, in multiple myeloma cells[J]. Cell Signal, 2019,60:136-145. DOI: 10.1016/j.cellsig.2019.04.012. doi: 10.1016/j.cellsig.2019.04.012 pmid: 31034872
[7]	Hervás-Marín D, Higgins F, Sanmartín O, et al. Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma[J]. PLoS One, 2019,14(12):e0223341. DOI: 10.1371/journal.pone.0223341. doi: 10.1371/journal.pone.0223341 pmid: 31860637
[8]	Yang Y, Wu R, Sargsyan D, et al. UVB drives different stages of epigenome alterations during progression of skin cancer[J]. Cancer Lett, 2019,449:20-30. DOI: 10.1016/j.canlet.2019.02.010. doi: 10.1016/j.canlet.2019.02.010 pmid: 30771437
[9]	Tam S, Yao CMK, Amit M, et al. Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck[J]. JAMA Otolaryngol Head Neck Surg, 2019,146(2):128-135. DOI: 10.1001/jamaoto.2019.3751. doi: 10.1001/jamaoto.2019.3751 pmid: 31804658
[10]	Jambusaria-Pahlajani A, Crow LD, Lowenstein S, et al. Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study[J]. Transpl Int, 2019,12:1259-1267. DOI: 10.1111/tri.13493.
[11]	Peters FS, Peeters AMA, Mandaviya PR, et al. Differentially methy-lated regions in T cells identify kidney transplant patients at risk for de novo skin cancer[J]. Clin Epigenetics, 2018,10:81. DOI: 10.1186/s13148-018-0519-7. doi: 10.1186/s13148-018-0519-7 pmid: 29946375
[12]	Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer[J]. Clin Exp Immunol, 2019,197(3):341-351. DOI: 10.1111/cei.13309. doi: 10.1111/cei.13309 pmid: 31059128
[13]	Gao X, Cheng Z, Yuan H, et al. K-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer[J]. J Cell Physiol, 2020,235(4):3905-3915. DOI: 10.1002/jcp.29284. doi: 10.1002/jcp.v235.4 pmid: 31642074
[14]	Ichise T, Yoshida N, Ichise H. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signaling-induced tumour formation in mice[J]. J Pathol, 2019,249(1):39-51. DOI: 10.1002/path.5279. doi: 10.1002/path.5279 pmid: 30953353
[15]	McHugh A, Fernandes K, South AP, et al. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity[J]. Oncotarget, 2018,9(29):20265-20281. DOI: 10.18632/oncotarget.24750. doi: 10.18632/oncotarget.24750 pmid: 29755650
[16]	McHugh A, Fernandes K, Chinner N, et al. The identification of potential therapeutic targets for cutaneous squamous cell carcinoma[J]. J Invest Dermatol, 2020,140(6):1154-1165.e5. DOI: 10.1016/j.jid.2019.09.024. doi: 10.1016/j.jid.2019.09.024 pmid: 31705877
[17]	Xu J, Meng Q, Li X, Yang H, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p[J]. Cancer Res, 2019,79(19):4882-4895. DOI: 10.1158/0008-5472.CAN-18-3880. doi: 10.1158/0008-5472.CAN-18-3880 pmid: 31409641
[18]	Vidovic D, Huynh TT, Konda P, et al. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells[J]. Cell Death Differ, 2020,27(1):363-378. DOI: 10.1038/s41418-019-0362-1. doi: 10.1038/s41418-019-0362-1 pmid: 31197235
[19]	He K, Li WX, Guan D, et al. Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets[J]. Funct Integr Genomics, 2019,19(4):645-658. DOI: 10.1007/s10142-019-00670-7. pmid: 30859354
[20]	Gong ZH, Zhou F, Shi C, et al. miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN[J]. Cell Mol Biol Lett, 2019,24:9. DOI: 10.1186/s11658-018-0131-z. doi: 10.1186/s11658-018-0131-z pmid: 30891072
[21]	Sand M, Bechara FG, Sand D, et al. Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma[J]. Epigenomics, 2016,8(4):501-518. DOI: 10.2217/epi-2015-0012. doi: 10.2217/epi-2015-0012 pmid: 27067026
[22]	Yu GJ, Sun Y, Zhang DW, et al. Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma[J]. Cancer Cell Int, 2019,19:270. DOI: 10.1186/s12935-019-0992-x. doi: 10.1186/s12935-019-0992-x pmid: 31649487

皮肤鳞状细胞癌表观遗传学发病机制

Epigenetic pathogenesis of cutaneous squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.
[2]	王裴, 崔曼莉, 张明鑫. 非编码RNA在结直肠癌早期诊断中的应用[J]. 国际肿瘤学杂志, 2021, 48(8): 502-506.
[3]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[4]	何苗, 范奎, 曹芳. 表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.
[5]	肖唱, 辛彦. 非编码RNA在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(9): 553-557.
[6]	张芳雍, 吴帆. 外泌体非编码RNA在肝癌液体活检中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(6): 378-381.
[7]	赵娟, 康晓静. 人端粒酶逆转录酶与皮肤恶性肿瘤 [J]. 国际肿瘤学杂志, 2019, 46(10): 634-637.
[8]	李智,许静凯,张博. 长非编码RNA在肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2018, 45(4): 220-222.
[9]	安亮,李俊,陈玉祥,方向. RASSF2A基因甲基化与大肠癌的相关性分析[J]. 国际肿瘤学杂志, 2018, 45(2): 77-79.
[10]	何晓琴,徐细明. 竞争性内源RNA在原发性肝癌中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(3): 231-234.
[11]	赵义, 燕善军, 王启之. UCA1在消化道肿瘤中的表达及作用机制[J]. 国际肿瘤学杂志, 2017, 44(2): 142-144.
[12]	顾漱溟,徐岷. 长非编码RNA UCA1作为竞争性内源RNA在调控肿瘤发生发展中的作用 [J]. 国际肿瘤学杂志, 2017, 44(12): 911-913.
[13]	李文清,侯劲松. 上皮间质转化的表观遗传调控[J]. 国际肿瘤学杂志, 2017, 44(12): 918-921.
[14]	张国华,张文波,蒋鹏程. 长非编码RNA在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(12): 937-939.
[15]	潘磊, 梁炜, 付敏, 钱晖, 许文荣, 蒋鹏程, 张徐. 长非编码RNA在消化系统肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2016, 43(8): 706-710.